Product image of Misolfa (Dienogest, Ethinylestradiol) supplied by GNH India

Misolfa

Active Ingredient:
Dienogest, Ethinylestradiol
Origin:
EU

Misolfa (Dienogest, Ethinylestradiol)

Dienogest/Ethinylestradiol, the active ingredients in Misolfa, are a combined estrogen‑progestogen oral contraceptive presented as a tablet for oral use. It treats prevention of pregnancy and helps regulate menstrual cycles in women of reproductive age.

GNH India supplies Misolfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is sourced from the European Union market and meets stringent quality and regulatory standards, ensuring reliable access for healthcare providers across multiple regions. GNH India’s distribution network enables timely delivery and compliance with local import requirements.

Manufacturer / TM Owner

Laboratoire Ccd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Misolfa, a combined estrogen‑progestogen oral contraceptive, is indicated for conditions related to reproductive hormone regulation.

  • Prevention of pregnancy: Provides reliable contraceptive protection by suppressing ovulation and altering cervical mucus.
  • Regulation of menstrual cycles: Helps achieve more predictable bleeding patterns and reduces menstrual discomfort.
  • Management of hormone‑related menstrual disorders: Used to stabilize cycle length and flow in women with irregular periods.

How It Works

  • Misolfa combines dienogest, a progestogenic agent, with ethinylestradiol, a synthetic estrogen. The estrogen component provides negative feedback on the hypothalamic‑pituitary axis, reducing the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH). Dienogest further suppresses ovulation, thickens cervical mucus, and induces endometrial changes that hinder implantation.

Side Effects

Like other combined oral contraceptives, Misolfa may be associated with a range of adverse reactions.

Common Side Effects

  • Nausea
  • Headache
  • Breast tenderness
  • Spotting or irregular bleeding

Serious or Rare Side Effects

  • Venous thromboembolism (deep‑vein thrombosis or pulmonary embolism)
  • Stroke or transient ischemic attack
  • Severe hypertension

Precautions & Warnings

Before prescribing Misolfa, clinicians should consider several precautionary measures to ensure patient safety.

  • Contraindications: Do not use in women with a history of thromboembolic disorders, estrogen‑dependent tumors, or uncontrolled hypertension.
  • Smoking: Avoid if over 35 years and a smoker, as cardiovascular risk increases.
  • Medication review: Assess concurrent use of enzyme‑inducing drugs that may reduce efficacy.
  • Pregnancy: Discontinue if pregnancy is confirmed; the product is not intended for use during pregnancy.
  • Breastfeeding: Use only if benefits outweigh potential risks, after consulting a healthcare professional.
  • Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Misolfa can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Enzyme inducers such as rifampicin, carbamazepine, or phenytoin may markedly reduce contraceptive effectiveness.
  • Certain SSRIs (e.g., fluoxetine) can increase estrogen levels, raising the risk of hepatic side effects.
  • Anticoagulants like warfarin may have altered effect due to estrogen‑induced changes in clotting factors.

Moderate Interactions (Monitor Closely)

  • Antifungals such as ketoconazole can raise plasma concentrations of ethinylestradiol.
  • Some antibiotics (e.g., tetracycline) may slightly diminish contraceptive efficacy.
  • Herbal supplements containing St. John’s wort may lower hormone levels, reducing protection.

Frequently Asked Questions

Misolfa is a combined estrogen‑progestogen oral tablet that is prescribed primarily for two purposes: preventing pregnancy by inhibiting ovulation and related hormonal changes, and helping to regulate menstrual cycles in women who experience irregular or heavy bleeding.

The ethinylestradiol component provides negative feedback to the hypothalamus and pituitary, suppressing the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH). Dienogest adds progestogenic activity that further blocks ovulation, thickens cervical mucus, and alters the endometrial lining, making implantation unlikely.

The dosing regimen for Misolfa is determined by the prescribing healthcare professional. Typically, the product is taken as one tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions are provided by the prescriber.

Misolfa is not intended for use during pregnancy; if pregnancy occurs, the medication should be stopped immediately. Regarding breastfeeding, the decision to continue or discontinue should be made by a healthcare provider after weighing the benefits to the mother against potential risks to the infant.

To place an order, submit an enquiry on the Misolfa product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Misolfa contains the progestogen dienogest, which offers a slightly different hormonal profile compared with more common progestins such as levonorgestrel. This may translate into variations in cycle control, acne improvement, or side‑effect tolerability, but overall contraceptive efficacy remains comparable to other approved combined oral pills.

Misolfa tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister pack or container. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability throughout its shelf life.

Misolfa is taken orally as a tablet, usually with water. It is recommended to take one tablet at the same time each day, following the cycle schedule provided by the prescriber, to maintain consistent hormone levels and optimal contraceptive effectiveness.

The most serious adverse events linked to combined oral contraceptives include venous thromboembolism, stroke, myocardial infarction, and severe hypertension. These risks are higher in women who smoke, are over 35 years of age, or have pre‑existing cardiovascular conditions.

Misolfa is contraindicated in women with a history of thromboembolic disease, estrogen‑dependent tumors (such as certain breast cancers), uncontrolled hypertension, active liver disease, or known hypersensitivity to any of its components. It should also be avoided in pregnant women.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Dienogest, Ethinylestradiol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT